| Literature DB >> 26679344 |
Anne H Rowley1,2,3, Kristine M Wylie4,5, Kwang-Youn A Kim6, Adam J Pink7, Amy Yang6, Rebecca Reindel7,8,9, Susan C Baker10, Stanford T Shulman7,8, Jan M Orenstein11, Mark W Lingen12, George M Weinstock5,13, Todd N Wylie4,5.
Abstract
BACKGROUND: Kawasaki Disease (KD) can cause potentially life-threatening coronary arteritis in young children, and has a likely infectious etiology. Transcriptome profiling is a powerful approach to investigate gene expression in diseased tissues. RNA sequencing of KD coronary arteries could elucidate the etiology and the host response, with the potential to improve KD diagnosis and/or treatment.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26679344 PMCID: PMC4683744 DOI: 10.1186/s12864-015-2323-5
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Clinical data on Kawasaki disease children whose coronary artery tissues were tested in this study
| Case # | Time since onset | KD therapy | Category | Pathology study case # [ | RNA tested by |
|---|---|---|---|---|---|
| KD1 | 2.5 weeks | None | Untreated | 4 | HTS, PCR |
| KD2 | 4 weeks | ASA, dipyridamole | Untreated | 16 | HTS |
| KD3 | 5 months | None | Untreated | 26 | HTS, PCR |
| KD4 | 7 months | None | Untreated | NA | HTS, PCR |
| KD5 | 3.5 weeks | IGIV, ASA, steroid | Treated | 11 | HTS, PCR |
| KD6 | 4 weeks | IGIV, ASA, steroid, infliximab | Treated | 13 | HTS, PCR |
| KD7 | 3 weeks | IGIV, ASA | Treated | 7 | HTS, PCR |
| KD8 | 5 weeks | IGIV, ASA, steroid | Treated | 18 | HTS |
HTS high-throughput RNA sequencing, PCR real-time reverse transcriptase PCR, ASA aspirin
Clinical data on control children whose coronary artery tissues were tested in this study
| Control # | Diagnosis | RNA tested by |
|---|---|---|
| C1 | Enterobacter sepsis, pulmonary hemorrhage, neurologic devastation from herpes simplex virus encephalitis | HTS |
| C2 | Pneumococcal meningitis, disseminated intravascular coagulation | HTS, PCR |
| C3 | Prematurity, neurologic devastation secondary to Serratia meningitis, chronic lung disease | HTS |
| C4 | Meconium aspiration, pulmonary hemorrhage | HTS |
| C5 | Developmental delay, seizures, fever | HTS |
| C6 | Prematurity, cerebral hemorrhage, bronchopulmonary dysplasia, and pneumonia | HTS, PCR |
| C7 | Cholestasis, renal tubular acidosis, agenesis corpus callosum, dehydration | HTS |
| C8 | Congenital diaphragmatic hernia, pulmonary hypoplasia | PCR |
| C9 | Hypotonia, subdural and liver hematomas | PCR |
| C10 | Congenital sacrococcygeal teratoma | PCR |
| C11 | Hypoplastic left heart, respiratory syncytial virus infection | PCR |
HTS high-throughput RNA sequencing, PCR real-time reverse transcriptase PCR
Fig. 1Workflow to determine differentially expressed molecular pathways in KD coronary arteries
Fig. 2a Left, coronary artery tissue section from KD patient 6, demonstrating subacute chronic (SA/C) inflammation and luminal myofibroblastic proliferation (LMP) with resultant narrowing of the arterial lumen that is filled with blood. Right, coronary artery tissue section from control patient 4, demonstrating normal histology without inflammation. Hematoxylin and eosin stains, M = media, A = adventitia; b Heatmap demonstrating differential gene expression in KD and control coronary artery tissues, with low expression in blue and high expression in red; c KD coronary artery gene expression does not cluster by treatment, patient age, or time since onset of KD. The lack of clustering of gene expression by treatment is likely due to persistent arteritis in the treated patients despite therapy
Top 25 upregulated pathways in kawasaki disease coronary arteries
| Upregulated pathways | # of differentially expressed genes |
|
|---|---|---|
| Primary immunodeficiency signaling | 26 | 5.65E-21 |
| Communication between innate and adaptive immune cells | 30 | 1.08E-17 |
| iCOS-iCOSL signaling in T helper cells | 32 | 3.12E-17 |
| Altered T cell and B cell signaling in rheumatoid arthritis | 29 | 3.84E-17 |
| B cell development | 17 | 3.62E-14 |
| CD28 signaling in T helper cells | 28 | 1.35E-12 |
| Role of NFAT in regulation of the immune response | 33 | 6.43E-12 |
| PKCθ signaling in T lymphocytes | 27 | 8.5E-12 |
| Autoimmune thyroid disease signaling | 17 | 5.1E-11 |
| Hematopoiesis from pluripotent stem cells | 17 | 1.06E-10 |
| T cell receptor signaling | 23 | 1.38E-10 |
| Antigen presentation pathway | 14 | 6.89E-10 |
| Calcium-induced T lymphocyte apoptosis | 18 | 7.03E-10 |
| Crosstalk between dendritic cells and natural killer cells | 21 | 9.61E-10 |
| Systemic lupus erythematosus signaling | 34 | 1.8E-09 |
| Allograft rejection signaling | 20 | 3.16E-09 |
| Graft-versus-host disease signaling | 15 | 3.7E-09 |
| T helper cell differentiation | 18 | 4.41E-09 |
| CTLA4 signaling in cytotoxic T lymphocytes | 20 | 4.84E-09 |
| Nur77 signaling in T lymphocytes | 16 | 6.42E-09 |
| Dendritic cell maturation | 29 | 8.49E-09 |
| Agranulocyte adhesion and diapedesis | 29 | 2.97E-08 |
| OX40 signaling pathway | 19 | 3.48E-08 |
| Natural killer cell signaling | 21 | 5.32E-08 |
| Hepatic fibrosis/Hepatic stellate cell activation | 29 | 7.53E-08 |
Fig. 3Expression levels of gene families in KD compared with control coronary arteries. a Upregulation of activated cytotoxic CD8 T lymphocyte genes in KD, b Upregulation of type I interferon-induced genes in KD, c Lack of differential expression of tumor necrosis factor α-induced genes in KD. Blue indicates low expression and red high expression
Type I interferon-stimulated genes differentially expressed in KD compared with childhood control coronary arteries
| Gene | Fold change |
|
|---|---|---|
| ADAMDEC1 | 20.5 | 2.6e-18 |
| AIM2 | 3.7 | 0.023 |
| ANKRD22 | 10.2 | 1.9e-07 |
| APOBEC3G | 3.5 | 0.023 |
| AQP9 | 4.9 | 1.7e-06 |
| BTN3A3 | 3.5 | 0.020 |
| C15orf48 | 4.0 | 0.0004 |
| CCL5 | 6.5 | 1.1e-05 |
| CD69 | 10.3 | 2.6e-09 |
| CD74 | 7.7 | 3.5e-05 |
| CLEC2B | 3.0 | 0.006 |
| CLEC4D | 3.4 | 0.029 |
| CLEC4E | 3.9 | 0.011 |
| CXCL9 | 48.0 | 1.2e-14 |
| CXCR4 | 14.7 | 2.9e-12 |
| EPSTI1 | 4.9 | 0.002 |
| FAM46C | 5.3 | 0.001 |
| GBP2 | 4.3 | 0.0005 |
| GBP5 | 14.7 | 8.8e-14 |
| GK | 2.6 | 0.0008 |
| HLA-F | 2.8 | 0.007 |
| HSH2D | 2.9 | 0.044 |
| IFI30 | 4.6 | 0.0002 |
| IFI44 | 3.3 | 0.022 |
| IFI44L | 4.2 | 4.6e-06 |
| IFIT2 | 3.3 | 0.029 |
| IL1RN | 2.8 | 0.020 |
| MSR1 | 5.8 | 0.002 |
| MT1H | 1.7 | 0.0009 |
| MX1 | 4.2 | 0.0002 |
| MX2 | 4.7 | 0.0005 |
| NCF1 | 4.1 | 0.004 |
| OAS1 | 4.3 | 0.008 |
| OAS2 | 5.0 | 0.0005 |
| OLR1 | 42.2 | 7.6e-19 |
| RGS1 | 17.0 | 1.3e-10 |
| RSAD2 | 4.1 | 0.002 |
| STAP1 | 7.4 | 1.3e-07 |
| TAGAP | 6.2 | 0.0001 |
| TFEC | 7.4 | 0.0009 |
| TNFSF13B | 4.2 | 0.010 |
| XAF1 | 3.3 | 0.005 |
| ZBP1 | 5.6 | 0.002 |
| AGPAT9 | −2.4 | 0.0008 |
| CES1 | −4.1 | 4.0e-05 |
| FNDC4 | −2.0 | 0.006 |
| MT1M | −2.5 | 0.029 |
| SAA1 | −5.3 | 6.4e-14 |
Fig. 4Heatmap showing viral sequences identified in KD and control coronary artery samples; none were KD-associated by Metastats analyses